

FORM 9

NOTICE OF ISSUANCE OR PROPOSED ISSUANCE OF LISTED SECURITIES

(or securities convertible or exchangeable into listed securities¹)

Name of Listed Issuer:

Symbol(s):

Mydecine Innovations Group Inc. (the "Issuer").

MYCO

Date: February 24, 2021 Is this an updating or amending Notice: Yes No

If yes provide date(s) of prior Notices: N/A

Issued and Outstanding Securities of Issuer Prior to Issuance: 180,418,760

Pricing

Date of news release announcing proposed issuance: February 24, 2021 or

Date of confidential request for price protection: N/A

Closing Market Price on Day Preceding the news release: \$0.465 or

Day preceding request for price protection: N/A

Closing

Number of securities to be issued: 92,654

Issued and outstanding securities following issuance: 180,511,414

Instructions:

1. For private placements (including debt settlement), complete tables 1A and 1B in Part 1 of this form.
2. Complete Table 1A – Summary for all purchasers, excluding those identified in Item 8.
3. Complete Table 1B – Related Persons only for Related Persons
4. If shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition) please proceed to Part 2 of this form.
5. An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10 – Notice of Proposed Transaction
6. Post the completed Form 9 to the CSE website in accordance with *Policy 6 – Distributions*. In addition, the completed form must be delivered to listings@thecse.com with an appendix that includes the information in Table 1B for ALL places.

Part 1. Private Placement

Table 1A – Summary

Each jurisdiction in which purchasers reside	Number of Purchasers	Price per Security	Total dollar value (CDN\$) raised in the jurisdiction
Manitoba	1	\$0.465	\$43,084.11
Total number of purchasers:	1		
Total dollar value of distribution in all jurisdictions:			\$43,084.11

Table 1B – Related Persons

Full Name & Municipality of Residence of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable) (CDN\$)	Prospectus Exemption	Total Securities Previously Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)
Nisaki Consulting Inc.	92,654	\$0.465	N/A	NI 45-106 Sec. 2.14 [Securities for debt]	Nil	Feb. 8, 2021	Arm's length

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: \$43,084.11.
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material.

Not applicable.

3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer:

Not applicable.

4. If securities are issued in forgiveness of indebtedness, provide details of the debt agreement(s) or and the agreement to exchange the debt for securities.

On February 8, 2021, the Issuer entered into a debt settlement agreement with Nisaki Consulting Inc. ("Nisaki"), pursuant to which the Issuer agreed to issue 92,654 common shares at a deemed price of \$0.465 per share to Nisaki to settle the Issuer's debt of \$43,083.70 owed to Nisaki.

5. Description of securities to be issued:

- (a) Class Common Shares.
- (b) Number 92,654.
- (c) Price per security \$0.465.
- (d) Voting rights One voting right per common share.

6. Provide the following information if warrants, (options) or other convertible securities are to be issued:

Not applicable.

7. Provide the following information if debt securities are to be issued:

Not applicable.

8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):

Not applicable.

9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship.

Not applicable.

10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).

Not applicable.

11. State whether the private placement will result in a change of control.

Not applicable.

12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders.

Not applicable.

13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

The Issuer confirms that each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102 Resale of Securities.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. the Issuer has obtained the express written consent of each applicable individual to:
 - (a) the disclosure of their information to the Exchange pursuant to this Form or otherwise pursuant to this filing; and
 - (b) the collection, use and disclosure of their information by the Exchange in the manner and for the purposes described in Appendix A or as otherwise identified by the Exchange, from time to time
4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
5. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated February 24, 2021.

David Joshua Bartch
Name of Director or Senior
Officer

"David Joshua Bartch"
Signature

CEO and Director
Official Capacity